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Sllmmsl-y 
Accessory  cell  surface  molecules,  such  as  T  cell  antigen  CD2  and  its  ligand lymphocyte 
function-associated antigen 3 (LFA-3; CD58), are critical costimulatory pathways for optimal 
T cell activation in response to antigens. Interaction of CD2 with cell surface LFA-3 not only 
increases T cell/accessory cell adhesion, but also induces signal transduction events involved in 
the regulation of T  cell responses.  In this report, we show that specific interactions of LFA-3 
with CD2 can result in T cell unresponsiveness  to antigenic or mitogenic stimuli in vitro. By 
deletion of certain regions of the extracellular domain of LFA-3, we localized the CD2 binding 
site to the first domain of LFA-3. We then demonstrated that a soluble, purified first domain-LFA- 
3/IgG1 fusion protein (LFA3TIP) interacts with CD2 and binds to the same CD2 epitope as 
purified multimeric or cell surface-expressed LFA-3. LFA3TIP inhibits tetanus toxoid, hepatitis 
B surface antigen, anti-CD3 mAb, Con A, and phytohemagglutinin  P-induced T cell proliferation, 
as well as xenogeneic and allogeneic mixed lymphocyte reactions (MLR).  Unlike anti-LFA-3 
or anti-CD2 monoclonal antibodies (mAbs) which inhibit T cell responses by blocking LFA- 
3/CD2 binding, LFA3TIP is capable of rendering T cells unresponsive to antigenic stimuli in 
situations where T  cell activation is independent of CD2/LFA-3 interactions. Furthermore, 
LFA3TIP, but not blocking anti-CD2 mAbs, is capable of inducing T cell unresponsiveness  to 
secondary stimulation in allogeneic MLR. This inhibition of T cell responses by LFA3TIP occurs 
through a different mechanism from that of mAbs to LFA-3 or CD2. 
l~ 
sponses of the immune system are centrally controlled by 
T  cell activity which is initiated through cellular in- 
teractions between T cells and APCs. The specificity of rec- 
ognition is  dictated by  the TCR complex (TCR-CD3), 
whereas optimal T cell responses are dependent on costimula- 
tory signals by accessory cell surface molecules, including 
CD2/LFA-3, LFA-1/intercellular adhesion molecule 1, CD28/ 
B7, CD4/class II, and CDS/class I (for reviews see references 
1-4). The multitude of cell surface antigens involved in T 
cell activation appears to be excessive  and their functions redun- 
dant. However, this multiplicity of interactions represents 
a finely tuned regulatory mechanism of T cell activation during 
specific stages of the immune response, involving sequential 
interactions and activation of individual surface antigens and 
their pathways (3, 5-7), physical linkage between surface struc- 
tures, and association of protein kinase and phosphatase ac- 
tivities (8, 9). Inhibition of any one of these costimulatory 
pathways with their respective mAbs is sufficient to inhibit 
T  cell responses. 
Human CD2 is a glycoprotein, expressed on all subsets 
of T lymphocytes, NK and LAK cells, and functions to op- 
timize antigen-specific and -independent T cell responses, not 
only by increasing cellular adhesion between cognate partners, 
but also by augmenting T  cell responses initiated through 
the TCR/CD3 engagement (1). It has also been suggested 
that CD2 has a regulatory role in T cell responses by trans- 
ducing a negative signal to T cells (10, 11). However,  so far 
it has not been clearly established  that the inhibition of T 
cell responses through CD2 is independent of blocking cel- 
lular adhesion. 
The CD2 ligand, LFA-3, is expressed on a large variety 
of cells as a transmembrane-integrated or phosphoinositol- 
linked surface glycoprotein (12-14). CD2/LFA-3 interactions 
transduce signals not only to T cells but also to interacting 
monocytes resulting in the secretion of cytokines capable of 
regulating T cell responses (15). Modulation of cell surface 
expression levels of both CD2 and LFA-3 has been impli- 
cated in playing a regulatory role in the antigen-specific re- 
sponses of various subsets of T cells (3, 5). Purified LFA-3 
in multimeric but not monomeric form potently costimu- 
lares T  cell responses  with mitogens or anti-CD2-specific 
mAbs in vitro (16). 
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lular regions each consists of two Ig-like domains which classify 
them as members of the Ig superfamily (17). By mAb epi- 
tope mapping and site-specific mutagenesis, the LFA-3 binding 
site on CD2 has been localized to two epitopes in the first 
domain of CD2 (18). 
We have analyzed the structural and functional require- 
ments for interactions of LFA-3 with CD2. We mapped the 
CD2 binding site to the first domain of  LFA-3 and constructed 
a dimeric first domain-LFA-3/IgG1 fusion protein. The effect 
of this purified fusion protein (LFA3TIP) on T cell responses 
was compared with that of the purified full-length mono- 
meric or multimeric LFA-3, and that of mAbs to LFA-3 or 
CD2.  LFA3TIP inhibits allogeneic and xenogeneic MLR, 
anti-CD3  mAb,  or  lectin-induced polyclonal,  as  well  as 
antigen-specific  T  cell activation in vitro. We demonstrate 
here that inhibition of T  cell proliferation by LFA3TIP is 
a function of its interaction with CD2, and that the mecha- 
nism of LFA3TIP inhibition is distinct from that of several 
CD2 or LFA-3-specific mAbs tested. LFA3TIP is capable of 
inhibiting T cell activation independent of blocking CD2/ 
LFAo3 interactions. 
Materials and Methods 
Determination of the CD2 Binding Domain on LFA-3.  Plasmid 
pHT16-6 containing the full-length cDNA for the transmembrane 
form of LFA-3 (14) was mutated using the gaped plasmid muta- 
genesis essentially  as described (19). LFA-3 deletion mutants have 
the following amino acids of the mature LFA-3 deleted: M57, 51 
to 60; M63, 111 to 120, M100, 11 to 70; M101, 71 to 130; and 
M102, 131 to 180. In all cases, Phe is being designated as the first 
residue of the mature LFA-3. Each deletion mutant was confirmed 
by DNA sequence analysis (20). Mutagenized LFA-3 cDNA was 
inserted into expression  vector pBG368FY, or its derivative  pMDR 
902 (a derivative  ofpBG312, which carries the DHFR gene; Rosa, 
M. D., unpublished observations) and resulting plasmids were used 
to transfect Chinese hamster ovary (CHO)  1  cells which are DHFR 
negative (CHO-DHFR(-) cells) as described (21). Methotrexate- 
resistant cells were assayed for LFA-3 cell surface expression by 
FACS  |  analysis  (FACStar  Plus|  Becton Dickinson & Co., Moun- 
tain View, CA) using rabbit anti-LFA-3  polyclonal  antibody (Rb202; 
Biogen,  Inc.) as primary  antibody  and FITC-conjugated goat 
anti-rabbit IgG to detect Rb202 binding. Cells positive for LFA-3 
expression were further  tested for binding of anti-LFA-3 mAbs 
TS2/9 (a gift of T. Springer, Center for Blood Research, Boston, 
MA), 7A6, and 1E6 (Biogen, Inc.) by FACS  |  analysis  with FITC- 
conjugated goat anti-murine  IgG. 
Construction and Expression of  lgGl Fusion Proteins.  The human 
IgG1 H chain C region containing the the hinge region, the C.2 
and  the  C,3  sequences, were isolated with  H  chain-specific 
primers by PCR amplification  of  cDNA from the RNA of COS-7 
cells that had been transfected with plasmids containing 3-kb 
genomic DNA inserts. The genomic DNA inserts had been iso- 
lated by digestion of the partial Sau3A human fibroblast genomic 
library  EMBL/SX  (a  gift  of Mark  Pasek, Biogen,  Inc.).  H 
1  Abbreviations used in this  paper: CHO, Chinese  hamster ovary;  h, human; 
HBsAg, hepatitis B surface  antigen; MLR, mixed lymphocyte  reaction; 
TT, tetanus toxoid. 
chain-specific oligonucleotide primers were designed so that the 
resulting C.2 and C. IgG1 PCR amplified  sequences were flanked 
by a 5' Sail and a 3' NotI restriction enzyme recognition site. The 
NH2-terminal 92 amino acid sequence of mature LFA-3, preceded 
by the LFA-3 signal sequence, was isolated by PCR amplification 
of pHT16-6 cDNA (14), using one primer containing a 5' NotI 
site and another primer containing  a Sail site at the 3' end. Amplified 
DNA fragments of the LFA-3  and the IgG1 sequences were ligated 
and inserted into an expression vector pSAB132 (a derivative of 
pJOD-S [21]). The resulting plasmid pSAB152 contains cDNA se- 
quences coding for the signal sequence and first 92 amino acids 
of LFA-3, for 10 amino acids of the hinge region, and for the full 
sequence of the C,2 and C,3 regions of IgG1, all flanked  by NotI 
restriction sites. The NotI fragment of pSAB152, coding for the 
LFA-3 fusion protein,  was  inserted into the  expression vector 
pMDR902, and the resulting plasmid, pMDR(92)Ig-3 was trans- 
fected into CHO-DHFR(-) cells. M57IgG1 fusion protein was 
constructed by PCR amplification of the LFA-3 deletion mutant, 
M57 cDNA sequences coding for the first 82 amino acids of the 
mature M57/LFA-3. Amplified  DNA was ligated to IgG1 sequences 
and inserted into the pSAB132 expression  vector as described above 
for LFA3TIP. The resulting plasmid pM57IgG1 was used to trans- 
fect CHO-DHFR(-) cells. A LFA-3/IgG1 fusion protein con- 
taining both domains of LFA-3 (LFA3FLIgG1)  was constructed 
exactly as described for LFA3TIP, except that the signal sequence 
and the first 183 amino acids of the extracellular  domain of LFA-3 
were amplified  and fused to the IgG1 sequences, as described above. 
The resulting plasmid pLFA3FLIgG1  was used to transfect CHO- 
DHFR(-) cells. Expression levels of all LFA-3 fusion proteins were 
amplified  by culturing transfected CHO cell lines in medium con- 
taining increasing  concentrations  of  methotrexate.  All proteins were 
purified from cultured medium by adsorption to protein A-Sepha- 
rose 4B (Pharmacia, Piscataway,  NJ). Multimeric phosphoinositol- 
linked LFA-3 (PI-LFA-3) and monomeric LFA-3 were purified as 
described (16). The CD4IgG1 fusion protein was constructed by 
ligating a PCR amplified DNA fragment coding for the NHz- 
terminal 180 amino acids of human CD4 to the PCR amplified 
fragment of the same human IgG1 sequences as had been used for 
LFA3TIP, followed by insertion into expression vector pSAB132. 
Expression in CHO cells and purification of CD4IgG1 protein was 
exactly as described for LFA3TIP. 
Cell  Binding Analysis.  CHO-DHFR(-)  cells and  CHO- 
DHFR(-)  cells transfected with mutated  or  wild-type LFA-3 
cDNA were grown in 6-well plates (Corning Inc., Coming, NY) 
at 10  s cells/well, washed with RPMI complete medium, and in- 
cubated with 5 x  10  s  Jurkat cells in RPMI and 10% fetal bovine 
serum for 4 h at 4~  Wells were washed gently three times with 
RPMI medium and examined  under the microscope  for rosette for- 
mation. 
Human (h) and sheep RBC rosetting to Jurkat cells was per- 
formed exactly as described previously (16). 
LFA3TIP and mAb Binding Analysis to CD2.  CD2 substitu- 
tion mutants were a gift of D. Brian Seed (Massachusetts General 
Hospital, Boston, MA). Transfection  of COS cells was carried out 
essentially as described (21) and CD2 expression levels were ana- 
lyzed using anti-CD2 mAb GD10 (a gift olD. Hess, Biogen, Inc.). 
Binding of all human IgG1 fusion proteins was detected by PE- 
conjugated  anti-human IgG,  and binding  of anti-CD2  mAbs 
TS2/18 (a gift ofT. Springer, Center for Blood Research, Boston, 
MA) and GD10 by FITC-conjugated anti-murine IgG (Jackson 
ImmunoResearch  Laboratories,  Inc., West Grove, PA) using FACS  | 
analysis. 
T Cell Proliferation Assays.  PBLs  from healthy volunteers were 
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For mixed lymphocyte reaction (MLR.), stimulator  cells were ei- 
ther allogeneic PBLs, murine  B cell tumor cells A20, or human 
B cell tumor cells JY (gift of Tim Springer), irradiated with 2,000 
rad for PBLs or 10,000 rad for tumor ceils in a ~/cell irradiator. 
For MLR with allogeneic PBLs as stimulators the responder/stimu- 
lator ratio was 1:1. With B cell tumor stimulators, a 5:1 ratio was 
used. Responder cells (1-2  x  10S/well) were incubated in RPMI 
medium supplemented  with 10% heat-inactivated FCS at 370C 
in 96-wall round-bottom plates (model 25850; Coming Inc.) for 
the  indicated  times,  pulsed  with  1 /~Ci [methyl-3H]thymidine 
(New England Nuclear, Boston, MA) for 12-15 h, and harvested 
using a 96-well harvester (Tomtec, Orange, CT). Anti-CD3 mAb, 
OKT3 (Ortho Pharmaceuticals, Raritan,  NJ) was used at a final 
concentration  of 3 ng/ml, and Tllz and Tl13 antibodies (gift of 
Dr.  Ellis Reinherz,  Dana Farber Cancer Institute,  Boston,  MA) 
were used at a 1:900 dilution of ascites. In all T cell activation assays, 
isotype control mAbs at 1-5/xg/ml were included. For murine mAbs 
we used MOPC21 at 5 #g/m1, and for all fusion proteins, purified 
hIgG at 1/~g/ml (Pierce, Rockford, IL). For mitogen, PHA-P, Con 
A (Sigma Chemical Co., St. Louis, MO), and antibody-stimulated 
T cell proliferation assays, PBLs were incubated for 3 d. Antigen- 
specific stimulated and MLR cultures were incubated for 5 d un- 
less otherwise indicated. 
Results 
CD2 Binds to the First Domain of LFA-3.  To analyze the 
structural  and functional requirements  of CD2/LFA-3 in- 
teractions,  we identified the LFA-3 sequences involved in these 
interactions.  Three mutant cDNAs of the extracellular do- 
main of LFA-3 were constructed and stably expressed in CHO 
cells: LFA-3 mutant M100 has a deletion of the first domain, 
M101 a deletion of the first half, and M102 a deletion of the 
second half of the second domain of LFA-3 (for sequence, 
see reference 14). All mutants contain the LFA-3 transmem- 
brane region intact  and are therefore expressed on the cell 
surface of transfected CHO cells. 
Expression levels of these LFA-3 deletion mutants in CHO 
cells were monitored through the binding of a rabbit poly- 
clonal antibody to LFA-3, P,  b202, by FACS  |  analysis  (Fig. 
1 a for all deletions). CHO cells positive for LFA-3 expres- 
sion were then analyzed for binding of anti-LFA-3 mAbs 7A6 
and TS2/9, mAbs that had previously been shown to block 
LFA-3/CD2 interactions  (3,  16).  Only mutants  M101 and 
M102 (each containing  a deletion in the second domain of 
LFA-3) showed binding of mAbs 7A6 and TS2/9. Deletion 
of the first domain of LFA-3 (as in M100) abolished binding 
of those blocking anti-LFA-3 mAbs (Fig.  1 b). Each LFA-3 
deletion mutant expressed in CHO cells,  was evaluated for 
its binding to CD2 by its ability to rosette CD2(+) Jurkat 
cells.  Control  CHO cells  and CHO cells  transfected with 
MIO0 cDNA (deletion of the first domain) did not bind Jurkat 
cells, as was evidenced by the lack of rosette formation. CHO 
cells transfected with wild-type LFA-3 or with LFA-3 that 
had either half of the second domain deleted (M101 and M102), 
rosetted Jurkat cells to the same extent  (data not  shown). 
This indicates that the presence of the first domain of LFA-3 
is required  for the interaction  of CD2 with  LFA-3. 
The correct conformation  of the first domain of LFA-3 
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Figure  1.  Anti-LFA-3 mAb binding analysis to various mutant forms 
of LFA-3. FACS  |  analysis of LFA-3 deletion mutants expressed in CHO 
cells. (Solid line) Background fluorescence of cells incubated with FITC- 
labeled secondary antibody. (a) Binding of rabbit polyclonal anti-LFA-3 
antibody, Rb202, at a 1:100 dilution of immune serum, to demonstrate 
the LFA-3 expression levels (dashed line). Binding of R.b202 was detected 
with FITC-labeled goat anti-rabbit IgG. (b) Binding of anti-LFA-3 mAbs 
7A6 (dotted line) and TS2/9 (dashed line) to the indicated cell lines, both 
at 10 #g/ml. Primary antibody binding was detected with fluorescein- 
conjugated goat anti-mouse IgG antibodies. For each experiment,  5  x 
10  s cells were used. 
is critical for the interaction of LFA-3 with CD2. This was 
suggested by the observation that a series of 10 amino acid 
deletions in the first domain all abolished Jurkat cell roset- 
ting (data not shown), as well as binding of mAbs 7A6 and 
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TS2/9 (a representative example, M57, which has residues 
51 to 60 deleted, is shown in Fig. 1). Deletions in the second 
domain of LFA-3 had no effect on either mAb or Jurkat cell 
binding (mAb binding to one deletion, M63 with residues 
111  to  120 deleted is shown in  Fig.  2;  rosetting  data not 
shown). 
The cDNA sequence coding for the first domain of LFA-3 
(residues 1 to 92 of mature LFA-3) was fused to the human 
IgG1 hinge region, C.2 and C.3 sequences and expressed in 
CHO cells, where it was secreted as a dimeric molecule of 
100-110 kD (a schematic is shown in Fig.  2).  This fusion 
protein,  LFA3TIP,  was purified from culture medium and 
tested for its binding to CD2 by its ability to block hR_BC 
or SR.BC rosetting  with CD2 + Jurkat cells.  Fig.  3  shows 
the  percent  inhibition  of  R_BC/Jurkat  cell  rosetting  by 
LFA3TIP; purified mutant LFA3-M57IgG1; purified, mul- 
timeric, or monomeric LFA-3; as well as anti-CD2 or anti- 
LFA-3 mAbs. Rosetting of both,  human  and sheep RBCs 
with Jurkat cells is inhibited by anti-CD2 mAb TS2/18, which 
is  specific  for  the  LFA-3  binding  epitope  Tllt,  and  by 
anti-human LFA-3 mAb 7A6 (which crossreacts with sheep 
LFA-3). Purified PI-LFA-3 inhibits rosetting  at a 300-fold 
lower concentration than does LFA3TIP (PI-LFA-3 inhibi- 
tion data for StLBC not  shown),  whereas 10 times higher 
concentrations of monomeric LFA-3 than of LFA3TIP is re- 
quired  for  the  same  ICs0  (Fig.  3  a  for  hILBC  and  b for 
StLBC). These differences in inhibitory activities between the 
various forms of LFA-3 are most likely due to their different 
multivalent structure. We had observed previously (16) that 
the extent of  Jurkat/RBC rosette inhibition by purified LFA-3 
is directly proportional to the number of monomeric LFA-3 
contained in its muhimeric complex. Therefore, the level of 
inhibition by LFA3TIP is most likely a function of its mul- 
tiple interactions  with CD2,  dictated by its dimeric struc- 
ture. Inhibition of rosetting by LFA3TIP is due to its direct 
interaction with CD2 and not a function of its IgG1 sequences. 
This was demonstrated with control LFA-3/IgG1 fusion pro- 
tein M57IgG1, which contains the same sequences as LFA3TIP 
except that residues 51 to 60 of LFA3TIP have been deleted. 
This deletion resulted in the loss of CD2 binding. M57IgG 
does not inhibit  RBC rosetting  (Fig.  3). 
LFA3TIP but Not Purified LFA-3 Inhibits In Vitro T  Cell 
Proliferation.  Optimal activation of T cells in vitro has been 
shown to be strongly dependent on CD2/LFA-3 interactions, 
and cell surface or purified LFA-3 can transmit  costimula- 
tory T call activation signals (1-3, 5, 22). We therefore tested 
the effect of purified LFA3TIP in several human in vitro T 
cell  activation  assays. In  contrast  with  purified  LFA-3, 
LFA3TIP  inhibits  specific  antigen,  mitogenic lectin  PHA 
(PHA-P), and anti-CD3 mAb, OKT3 induced T cell prolifer- 
ation,  as well as allogeneic and xenogeneic MLRs. 
Human PBLs were isolated on a Ficoll-Hypaque gradient 
and incubated with 0.1/~g/ml PHA-P in the presence or ab- 
sence of LFA3TIP, purified muhimeric LFA-3 (PI-LFA-3), 
or mAbs to CD2 and LFA-3. Addition of PI-LFA-3 to PHA-P 
activated PBLs causes a twofold increase in PBL proliferation 
over that  seen with  PHA-P activation  alone.  In contrast, 
LFA3TIP inhibits PHA-P activated PBL proliferation by 50%. 
Anti-CD2 mAb, TS2/18,  and anti-LFA-3 mAb 1E6,  both 
of which block CD2/LFA-3 interactions, inhibit the PHA-P 
stimulated proliferation by >90%  (Fig.  4 a). 
LFA3TIP  is  also  capable  of inhibiting  proliferation  of 
memory T cells in vitro in response to recall antigens. PBLs 
from donors that had previously been vaccinated with tetanus 
toxoid (TT) or hepatitis B  surface antigen  (HBsAg), were 
stimulated in vitro with TT or HBsAg. T cell proliferation 
to these antigens was inhibited by anti-LFA-3 mAb TS2/9 
(data not shown), anti-CD2 mAb TS2/18, and LFA3TIP (Fig. 
4 b). LFA3TIP and mAbs inhibit T  cell proliferation in re- 
sponse to TT by 70%  and to HBsAg by 85%. 
As observed in  the  PHA-P stimulated  T  cell response, 
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Figure 3.  Inhibition ofJurkat/RBC  rosetting by LFA-3 
proteins and mAbs. (a) Human RBCs/Jurkat rosetting: (b) 
SRBC/Jurkat rosetting in the presence of M57IgG1 (0); 
monomeric LFA-3 (￿9  LFA3TIP  (ll); anti-LFA-3  mAb (O); 
anti-CD2 mAb TS2/18 (D); PI-LFA-3 (A) for hRBCs only. 
Protein concentrations in #g/ml. 
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Figure 4.  Effect  of antibodies, PI-LFA-3, LFA3TIP2 
on mitogen or specific  antigen-induced  T cell prolifera- 
tion. (a) PHA-induced  T cell  proliferation.  Human PBLs 
were incubated with 0.1/~g/ml PHA-P in the presence 
or absence  of  LFA3TIP,  PI-LFA-3,  anti-CD2 mAb TS2/18, 
or anti-LFA-3  mAb 1E6 (all at 5/~g/ml). Incubation  was 
carried out for 3 d and T cell proliferation  determined 
by incorporation  of [3H]thymidine  for 12 h. (b) T cell re- 
sponses to TT and HBsAg. Inhibition by LFA3TIP  and 
TS2/18 (both at 2/tg/ml)  of T cell proliferation  in re- 
sponse to TT and HBsAg. PBLs (10  s) from previously 
vaccinated donors were incubated with the indicated 
amount of antigen for 5 d, after which they were pulsed 
with  1 /zCi [3H]thymidine for 12  h.  TT, 2 #g/ml; 
HBsAg, 2 ,ug/ml. 
LFA3TIP and purified LFA-3 also have different effects on 
allogeneic MLR. Fig.  5 shows the effect of LFA3TIP, anti- 
CD2, or anti-LFA-3 mAbs, purified LFA-3, and a series of 
control fusion proteins on allogeneic MLR. Data was con- 
verted to percent inhibition, which allowed us to present the 
average results obtained in a series of separate MLRs. mAbs 
to LFA-3 or CD2, as well as LFA3TIP, inhibited T  cell re- 
sponses between 70 and 92%. Purified PI-LFA-3 or mono- 
meric LFA-3 had no effect on T  cell proliferation. Using 
FAC~ analysis, we demonstrated that FITC-labeled PI-LFA-3 
binds to CD2 on human PBLs during MLR (Wallner, B., 
and A. Frey, unpublished observation). The lack of inhibi- 
tion is therefore not due to the lack of PI-LFA-3 binding. 
To demonstrate that the inhibitory activity of LFA3TIP is 
a function of its direct interaction with CD2 and is not due 
to its engagement of FcR on APCs,  two IgG1 fusion pro- 
teins that do not bind to CD2 (M57IgG1 and CD4IgG1), 
as well as purified human IgG, were used as controls. CD4- 
IgG1 is a fusion protein consisting of the first 180 residues 
of CD4 attached to the same IgG1 sequences as LFA3TIP. 
CD4IgG1 and M57IgG1 were expressed in CHO cells and 
purified by the same procedure as LFA3TIP. These proteins 
had no effect on T cell proliferation in MLR (Fig. 5). M57IgG1 
or purified human IgG1 added in excess to MLR cultures 
which also contained LFA3TIP had no effect on the inhibi- 
tion of MLR by LFA3TIP (data not shown). As a further 
control, we subjected culture medium from mock-transfected 
CHO cells to the same purification procedure as LFA3TIP 
containing culture medium. This preparation had no effect 
on MLR. 
LFA3 TIP Induces T Cell Unresponsiveness to Repeated Stirau- 
/us.  In contrast with anti-CD2 mAb TS2/18, LFA3TIP is 
capable of inducing sustained T  cell unresponsiveness in an 
aUogeneic MLR. Allogeneic PBLs were incubated in the ab- 
sence or presence of LFA3TIP or mAb TS2/18 for 2 d, PBLs 
were then washed to remove LFA3TIP or TS2/18 (removal 
was demonstrated by FACS  |  analysis as described in Materials 
and Methods; data not shown), and responders were restimu- 
lated with the initial stimulator cells for another 5 d in the 
absence of LFA3TIP or TS2/18 (in Fig.  6 a,  washed).  As 
a control, MLR cuhures were incubated for 5 d in the pres- 
ence of either LFA3TIP or TS2/18 (Fig. 6 a, unwashed). Both 
LFA3TIP and TS2/18 inhibited T  cell proliferation in these 
cultures. In the washed cultures, which had originally been 
incubated with TS2/18, T cells regained their responsiveness 
to the stimulator cells. The extent of T cell proliferation was 
similar to that of the medium control of the washed cul- 
tures. However, cells originally inhibited by LFA3TIP remained 
unresponsive to the secondary stimulus throughout the in- 
cubation period. 
The T  cell unresponsiveness induced by LFA3TIP is not 
due to a general antiproliferative effect of LFA3TIP. Fig. 6 
b shows an allogeneic MLR where PBLs were incubated with 
or without LFA3TIP for 5 d. LFA3TIP inhibited this MLR 
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Figure  5.  Effect  of  various  forms  of  LFA-3  proteins  or mAbs 
to CD2 or LFA-3 on allogeneic  MLR. Responder  PBLs (105 
ceils) were stimulated with irradiated allogendc PBLs at a 
ratio of 1:1 for 5 d in the presence  or absence  of the indicated 
proteins: anti-LFA-3 mAbs 7A6 and 1E6; anti-CD2 mAb 
TS2/18; LFA3TIP;  M57LFA-3 (a M57/IgG1 fusion  protein); 
muhimeric (PI-LFA3) and monomeric  (mon. LFA-3) LFA-3; 
CD4/IgG1 fusion  protein, CD4-IgG (all at 1 #g/m1); buffer 
control (mock) which was obtained  by subjecting CHO cul- 
ture medium to the same  purification  procedure  as LFA3TIP; 
and purified human IgG at 1/~g/ml (A-IgG). Percent  inhibi- 
tion is that over  medium control. 
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Figure  6.  Induction of unresponsiveness by LFA3TIP to secondary stimuli in allogeneic MLR.  (a) (Unwashed)  Responder PBLs (103) were incubated 
with allogeneic stimulator cells at a ratio of 1:1 in the presence of LFA3TIP or TS2/18 (both at 1.5 #g/ml) for 2 d, restimulated with fresh stimulator 
cells,  and continued to be incubated for 5  d. (Washed)  Incubations were for 2  d  in the presence of LFA3TIP  or TS2/18.  Cultures  were washed on 
day 2,  fresh stimulator cells were added,  and incubations were continued for 5  d  in the absence of LFA3TIP  or TS2/18.  All cultures were pulsed 
with 1/*C/well,  [3H]thymidine for 12 h  and harvested. (b) T  cells remain responsive to PHA-P or Con A  stimulus after inhibition by LFA3TIP.  Re- 
sponder PBLs (103 cells/well) were incubated with irradiated allogeneic stimulator PBLs (103) in the presence or absence of LFA3TIP for 5 d. At that 
time,  Con A  (at 2  #g/ml)  or PHA-P  (at  1 /zg/ml) were added to cultures indicated,  and incubation was continued for 2  cl.  Cultures  were pulsed 
with  1/~Ci  [3H]thymidine overnight and harvested. 
by 90%. After 5 d, either Con A or PHA-P were added to 
cultures containing LFA3TIP or medium alone for 2 d. Both 
PHA-P and Con A augmented T  cell proliferation,  even in 
the presence of LFA3TIP. The extent of T cell proliferation 
in  response  to  PHA-P and  Con  A  in  cultures  containing 
LFA3TIP is less than that in the medium control.  This re- 
sult is consistent with our previous finding  that  LFA3TIP 
inhibits  PHA-P-induced T  cell proliferation.  Thus T  cells 
are still responsive to mitogenic activation,  indicating  that 
LFA3TIP does not inhibit responses by rendering T cells resis- 
tant to activation in general. Furthermore,  LFA3TIP added 
to cultures of T  or B tumor cell lines did not inhibit  their 
proliferation  (data not  shown). 
The Mechanism by which LFA3TIP Inhibits T Cell Responses 
Is Different  from that of mAbs.  Although, both LFA3TIP and 
mAbs to CD2 or LFA-3 showed similar inhibitory activity 
of RBC/Jurkat  cell rosetting,  for  PHA-P-induced  T  cell 
proliferation,  and for primary allogeneic MLR,  the ability 
of LFA3TIP to induce T cell unresponsiveness to secondary 
stimulus in allogeneic MLR indicated that its mechanisms 
of inhibition are different from those of mAbs. The following 
experiments  were conducted to obtain further  evidence of 
its different mechanism. 
Optimal  stimulation  of T  cell responses with  anti-CD3 
mAbs has been shown to depend on the experimental setup 
and on the specific anti-CD3 mAbs used (23, 24). Here we 
compared the effect of LFA3TIP in solution on soluble OKT3- 
stimulated PBL proliferation,  with  the effect of anti-CD2 
and anti-LFA3 mAbs. Under our experimental conditions, 
neither anti-CD2 mAbs, TS2/18 (Fig.  7, a and b) nor Tlll 
(data not shown), nor anti-LFA-3 mAb 1E6 (Fig. 7 a) affected 
T cell proliferation even when added at high concentrations. 
In contrast,  LFA3TIP inhibited  the OKT3-induced  T  cell 
proliferation in a dose-dependent manner (Fig. 7 b) achieving 
85% inhibition at 1/,g/ml (see Fig. 9 a). To exclude the pos- 
sibility that the inhibition  of the OKT3 induced T  cell re- 
sponse by LFA3TIP is solely due to the engagement of FcRs 
on accessory cells by the IgG1 portion of LFA3TIP, purified 
human IgG was used as a control.  Even at high concentra- 
tions  (10  /,g/ml)  human  IgG  had  no  effect  on  OKT3- 
stimulated  T  cell proliferation  (Fig.  7 b). 
The difference in the inhibitory mechanisms of LFA3TIP 
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Figure  7.  Effect  of LFA3TIP  on  OKT3- 
induced T  cell responses.  (a) T  cell prolifera- 
tion in response to OKT3. PBLs (10  3 per well) 
were incubated with OKT3  (3 ng/ml) in the 
presence or absence of LFA3TIP  (1  /~g/m]), 
anti-CD2 mAb TS2/18,  or anti-LFA-3 mAb 
1E6 (both at 1/*g/ml) as indicated for 3 d. On 
day 3, 1/~Ci [3H]thymidine was added to each 
incubation for 12 h before cells were harvested. 
(b) Inhibition of OKT3 (3 ng/ml) stimulated 
T  cell proliferation by increasing concentrations 
of  LFA3TIP  (~),  anti-CD2  TS2/18  (O), 
purified human IgG1  (A),  and OKT3  alone 
(O). Assay conditions were exactly as described 
in (a). 
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T cell activation occurs independently of LFA-3/CD2 inter- 
actions. In a xenogeneic MLtL, where human PBLs are stimu- 
lated with irradiated murine A20 cells (B lymphoma cell line), 
T  cell proliferation is not dependent on the interaction of 
human CD2 with the mouse equivalent of LFA-3. In this 
system, as can be expected, neither anti-LFA-3 (which does 
not bind to murine A20 cells) nor anti-CD2 (which binds 
to human PBLs) mAbs reduce the response to A20 cells (Fig. 
8 a; anti-LFA-3, data not shown).  However, LFA3TIP in- 
hibits this xenogeneic MLIL by 80% when added on day 0 
of cultures. When JY cells  (human B lymphoma cell line) 
are used as stimulator cells in allogeneic MLR, the activation 
of T cell proliferation is in part facilitated by the interaction 
of LFA-3 with CD2.  Therefore, anti-LFA-3 mAbs  1E6 or 
TS2/9 (data not shown) and anti-CD2 mAb TS2/18 inhibit 
T cell proliferation in response to JY cells. LFA3TIP also in- 
hibits this response to the same extent as mAbs (Fig. 8 b). 
mAbs to LFA-3 (data not shown) or to CD2 are only inhibi- 
tory when added on day 0 or I of incubation (Fig. 8 b). Later 
additions have no effect on T  cell proliferation. LFA3TIP, 
on the other hand, is capable of inhibiting both the aUogeneic 
and xenogeneic MLR, even when added up to 4 d after the 
MLR cultures were started. 
LFA3TIP Does Not Inhibit T  Cell Proliferation Stimulated 
Directly through CD2.  In all the experiments described above, 
LFA3TIP had an inhibitory effect on T  cell responses if the 
stimulus to T  ceils occurred in part through TCR engage- 
ment. However, when T cells were stimulated to proliferate 
by direct interaction with the CD2 receptor by a combina- 
tion of activating anti-CD2 mAbs, LFA3TIP showed no effect 
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Figure 9.  Percent  activation  of T cell proliferation  in response to ac- 
tivating anti-CD2 mAbs. 10  ~  PBLs were incubated with anti-CD2 mAbs 
as indicated (1:100 dilution of ascites), alone, or in combination with 
LFA3TIP (1/xg/ml) or PI-LFA-3 (1 #g/ml) for 3 d. T cell proliferation 
was detected  by incorporation  of [3H]thymidine  (1 #Ci/well for 12 h). 
Base value is that of T cell proliferation  in medium alone. 
on T  cell proliferation. T  cells can be optimally stimulated 
by a combination of anti-CD2 mAbs Tl12 and Tl13 (1; and 
Fig.  9).  Purified muhimeric LFA-3 (PI-LFA-3) effectively 
replaces mAb Tl12 in the augmentation of T  cell prolifera- 
tion  with  mAb  Tl13,  but  has  no  additional  stimulatory 
effect on T  cell proliferation in the presence of both mAbs. 
Even though LFA3TIP binds to the same CD2 epitope as 
PI-LFA-3, its binding does not costimulate T cell prolifera- 
tion elicited by either mAb  Tl12  or mAb  Tl13  (Fig.  9). 
When added to cultures that had been stimulated by the com- 
bination of mAbs Tl12 plus Tl13, LFA3TIP has  neither a 
stimulatory nor an inhibitory effect on T  cell proliferation. 
This lack of inhibition by LFA3TIP is not due to its compe- 
tition by mAbs  Tl12 or Tl13 for CD2 binding sites.  We 
demonstrated this by binding analyses shown in Fig. 10. We 
further confirmed by FACS  ® analysis, that LFA3TIP is bound 
to T cells during the antibody stimulation in these assays (data 
not shown). 
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Figure 8.  Inhibition  of allogeneic and xenogeneic  MLR by LFA3TIP 
and anti-CD2 mAb TS2/18. Effect  of  delayed  additions  of  TS2/18, purified 
human IgG (HIgG), and LFA3TIP (all at 5 #g/ml) on: (a) xenogeneic 
MLR (_420)  and (b) atlogeneic  MLR (JY). Numbers  under each  bar indi- 
cate day of addition of the respective  proteins. Day 0 is the first day of 
MLR. MLR assay  conditions  were  as described  in Materials  and Methods. 
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Figure 10.  FACS  ® analysis of LFA3TIP and mAb binding competi- 
tion to CD2 + Jurkat cells. (Tracings  1) PE-labeled  goat anti-human IgG 
antibody (secondary  antibody  control)  at 17 #g/m1; (tracings  2) binding 
of LFA3TIP in the absence of anti-CD2 mAbs; (tracings 3-6) binding 
of LFA3TIP  in the presence  of anti-CD2 mAbs Tl12 (3), Tl13 (4), Tlll 
(5), or TS2/18 (6). mAbs Tl11, Tl12, Tl13 were at a 1:100 dilution of 
ascites; mAb TS2/18 at 10/~g/ml. LFA3TIP  was present at 10/~g/mt. 
Units fluorescence  are arbitrary units. 
217  Miller  et al. LFA3TIP Binds to the Same CD2 Epitopes as a Full-Length 
LFA-3/IgGI Fusion and Cell Surface LFA-3.  Since  the effect 
of LFA3TIP on T cell activation was different from that of 
purified full-length LFA-3 and, in several  assays, different from 
the effect of anti-CD2 mAbs, it was of interest to determine 
whether these differences were a function of the one domain 
structure of LFA3TIP. We therefore constructed an LFA- 
3/IgG1 fusion protein (LFA3FLIgG1; Fig. 2), that contained 
both extraceUular domains of LFA-3, and compared its CD2 
binding properties with those of  LFA3TIP and mAbs to CD2. 
It had previously been established that the interaction of 
CD2 with purified LFA-3 or LFA-3 expressed on human 
RBCs, can be blocked with anti-CD2 mAbs specific for the 
Tlll epitope (mAbs Tll1 or TS2/18). Binding competition 
analysis of LFA3TIP with these blocking anti-CD2 mAbs 
to CD2 on Jurkat cells or on human PBLs indicated  that 
LFA3TIP  binds  to  the  same  CD2  epitope  as  T11t and 
TS2/18.  For this analysis, Jurkat cells were incubated with 
LFA3TIP in the absence (Fig. 10, a and b, tracing 2) or in 
the presence of anti-CD2 mAbs to specific  CD2 epitopes (Fig. 
10, a and b, tracings 3-6). LFA3TIP or LFA3FLIgG1 binding 
was detected by PE-conjugated anti-human IgG antibodies. 
Loss of PE-cell surface fluorescence in the presence of anti- 
CD2 mAbs was interpreted as loss of LFA3TIP binding. Coin- 
cubation of  Jurkat cells with LFA3TIP and either anti-CD2 
mAb TS2/18  or Tl11,  both of which are specific for the 
LFA-3 binding epitope on CD2, reduced PE-surface fluores- 
cence to almost background levels (Fig. 10 b, tracings 5 and 
6). This indicated that these mAbs compete for the LFA3TIP 
binding site on CD2. On the other hand, mAbs to the CD2 
epitope Tl12, located in the first domain, and to the epitope 
Tllz, located in the second domain (mAbs Tl12 and Tl13, 
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Figure  11.  mAb and LFA3TIP binding analysis to mutant CD2 expressing COS cells. COS cells transfected with the wild-type or mutant CD2 
cDNAs (K48N; L99S) were incubated with either mAb GD10, to demonstrate expression levels of CD2, or with LFA3TIP or LFA3FLIgG1, Binding 
of the IgG1 fusion proteins was detected by PE-conjugated goat anti-human IgG and binding of GDIO with FITC-conjugated  goat anti-murine IgG. 
(Tracing 1) In all graphs represents background fluorescence. (Tracings 2) In each group, represent the fluorescence intensity obtained when cells were 
incubated with 10/~g/ml LFA3TIP, FLLFA3IgG1, or mAb GD10.  (Tracing 3) Binding of LFA3TIP or FLLFA3IgG at  1 /~g/ml. (2~axes) Number 
of cells; (x-axes)  arbitrary  units of fluorescence. 
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10 a, tracings 3 and 4, respectively). To confirm that mAbs 
Tl12  and  Tl13  bind  to  Jurkat  cells in  the  presence  of 
LFA3TIP, a two-color FACS  |  analysis was performed. Anti- 
CD2 mAbs were detected with FITC-conjugated anti-mouse 
IgG and LFA3TIP with PE-labeled anti-human IgG. Both 
mAbs and LFA3TIP are able to bind simultaneously to CD2 
(data not shown), thus indicating distinct binding epitopes. 
The same binding properties  were determined for LFA3- 
FLIgG1  (data not shown). 
To fine-map the LFA3TIP binding epitope on human CD2, 
a series of CD2 variants with single amino acid substitutions 
either in epitope I, II, or III, as well as wild-type CD2, were 
expressed in COS-7 cells and used for binding analysis of 
LFA3TIP. Peterson and Seed (18) had developed these CD2 
mutants to map the LFA-3 binding epitopes on CD2.  We 
monitored expression levels of mutant or wild-type CD2 on 
the cell surface of CD2-transfected COS cells with anti-CD2 
mAb GD10, which is specific to a newly defined CD2 epi- 
tope not involved in the LFA-3/CD2 interactions  (Miller, 
G.,  and D.  Hess,  unpublished  observations;  binding data 
shown in Fig. 11, bottom row), Individual substitutions  of 
CD2 residues in the Tlll epitope (region II, domain 1) (L99 
to S, K87 to Y, Y91 to Q, and Q95 to E), abolished LFA3TIP 
or LFA3FLIgG1 binding to these mutants even when added 
at high concentrations (10 #g/ml). Binding data for one of 
these mutants (L99 to S) is shown in Fig. 11, right column. 
Binding of mAb Tlll to all of these mutants and binding 
of TS2/18 to all but substitution Q95E was also eliminated 
(data not shown). Binding of mAb Tl12 (specific for region 
I, domain 1) and mAb Tl13 (specific for region III in do- 
main 2) to these Tlll epitope mutants was not affected (data 
not shown). CD2 mutants in region I (Tl12 epitope) bound 
LFA3TIP and LFA3FLIgG1 with much lower affinity than 
wild-type CD2. These mutants had the following single amino 
acid substitutions:  K48 to N, K48 to M, K46 to N, AS0 
to E, and Q51 to L. Only at high concentrations (10 #g/ml) 
and not at 1/~g/ml was binding of LFA3TIP detectable (data 
for substitution K48N shown in Fig.  11,  middle column, 
tracing 2 for 10 #g/ml and tracing 3 for 1 #g/ml). Binding 
patterns for purified FITC-labeled PI-LFA-3 to all mutants 
tested were identical to that for LFA3TIP (data not shown). 
Discussion 
By deletion analyses of the extracellular region of LFA-3, 
we localized  the CD2 binding site to the first domain of  LFA-3. 
The extracellular regions  of both CD2 and LFA-3 consist 
of two Ig-like domains and their primary, and secondary struc- 
tures show a high degree of homology. The structural similar- 
ities between this ligand/receptor pair are emphasized by our 
finding that the mutual interactions occur through their respec- 
tive first domains. Using this binding information, we con- 
structed an LFA-3 domain 1/IgG1 fusion protein and exam- 
ined its effect on T  cell responses. 
ResUlts described here suggest that under specific condi- 
tions,  interactions  between CD2 and LFA-3 can represent 
a potential negative regulatory mechanism for T cell responses. 
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The LFA-3/IgG1  fusion protein, LFA3TIP, is capable of in- 
hibiting T cell responses in a series of in vitro T cell activa- 
tion assays. LFA3TIP  inhibited allogeneic and xenogeneic 
MLR, TT, HBsAg, and mAb OKT3-induced T cell responses, 
as well as T cell activation by PHA-P and Con A. The mech- 
anism by which LFA3TIP inhibits T cells is not clear, but 
it appears to be distinct from that ofmAbs to CD2 or LFA-3, 
which block CD2/LFA-3 interactions and cellular adhesion. 
In contrast with these mAbs,  LFA3TIP can interfere with 
T cell activation in situations where CD2/LFA-3 interactions 
are not required. This was best demonstrated in a xenogeneic 
MLR where human PBLs proliferate in response to murine 
A20 cells. Costimulatory signals in this MLR are supplied 
by interactions of accessory cell surface antigens other than 
human CD2 and the murine LFA-3 analogue, mAbs to human 
CD2 and LFA-3 which block human allogeneic MLR there- 
fore have no effect on T cell proliferation in response to A20 
cells in these xenogeneic MLR responses. LFA3TIP, how- 
ever, interacts with human T cells in such a manner that sub- 
sequent T cell activation signals by A20 cells have no effect. 
This inhibition by LFA3TIP, but not by mAbs to human 
CD2 or LFA-3, was even observed when LFA3TIP was added 
up to 4 d after the initial T cell stimulus in allogeneic MLR, 
which indicates that LFA3TIP is capable of  inhibiting prolifer- 
ation of already partially  or even fully activated T  cells. 
In all T cell activation assays described here, LFA3TIP ex- 
hibited its effect only when T  cell activation was, at least 
in part, elicited through simultaneous TCR/CD3 complex 
activation. T cell activation through direct stimulation of the 
CD2 molecule by a combination of activating anti-CD2 mAbs 
was not affected  by LFA3TIP. A potential mechanism by which 
LFA3TIP could inhibit T cell activation is through the inhi- 
bition of CD2 conformational changes. It has been suggested 
that binding of the anti-CD2 mAb Tl12 to CD2 induces 
a conformational change of CD2 so that the second activa- 
tion epitope Tl13 is upregulated (5). Furthermore, an anti- 
CD3 mAb $34, upon binding to CD3, has been reported 
to induce a similar conformational change of CD2,  trans- 
forming it  to  its  activated  state  (23).  It can  therefore  be 
hypothesized that during the initial interactions between T 
cells and APCs, which are facilitated by the TCR-CD3 com- 
plex and the MHC-Ag complex, upregulation of the Tl13 
epitope occurs. Subsequent interactions of CD2 with LFA-3 
on the APC then transduces an activation signal to T cells. 
Binding of LFA3TIP to CD2 during these initial interactions 
potentially inhibits  these conformational changes and thus 
prevents the second signal. In the in vitro assays described 
here, this inhibition is ~parently overcome  by the simultaneous 
presence of mAbs Tl12 and Tl13. However, several data de- 
scribed in this manuscript do not fully support this theory 
of interference by LFA3TIP with conformational changes. 
For example, the observation that LFA3TIP, but not mAbs 
to LFA-3 or CD2 can inhibit T cell proliferation even  when 
added to cultures up to 4 d after the initial T cell stimulation 
has occurred, together with the observation that LFA3TIP 
can inhibit xenogeneic MLR responses, is an indication that 
LFA3TIP  transduces a negative signal to T  cells, indepen- 
dent  of early  LFA-3/CD2  interactions.  Furthermore the finding that LFA3TIP, but not blocking mAbs, can induce 
lasting T cell unresponsiveness to repeated stimuli, suggests 
a mechanism other than interference with the initial cellular 
interactions. 
Clearly, the mechanism of inhibition by LFA3TIP is not 
merely a disruption of cellular adhesion, and thus is different 
from that of  blocking mAbs to LFA-3 and CD2. This differ- 
ence was demonstrated not only by the effect of LFA3TIP 
on xenogeneic MLK and by its induction of T cell anergy, 
but also by its inhibition of OKT3-induced T cell prolifera- 
tion. Activation of T cell proliferation  in vitro by mAbs specific 
for the CD3  complex are strongly dependent on the ex- 
perimental design and on the anti-CD3 mAbs used. The effect 
of anti-CD2 mAbs on anti-CD3 mAb-induced T cell acti- 
vation has been variable (23, 24). In our experimental setup 
stimulation of T cell proliferation by soluble anti-CD3 mAb, 
OKT3 was inhibited by LFA3TIP, but neither anti-CD2 nor 
anti-LFA-3 mAbs were able to inhibit this activation. It has 
been demonstrated  by a number of different laboratories that 
the signal transduction events elicited through the TCR-CD3 
complex and through CD2 are identical and functionally in- 
teract to regulate antigen-dependent T cell responses (9, 25, 
26). CD2 is also functionally  associated with other accessory 
cell-dependent  T cell activation pathways. Increased pp56  ~k 
tyrosine kinase activity has been reported in CD2-stimulated 
cells (27, 28) and the CD45-associated phosphatase activity 
has been suggested as a potential regulatory mechanism for 
CD2-induced phosphotyrosine kinase activity (29, 30). It is 
therefore likely that LFA3TIP through its binding to CD2, 
under conditions where TCR/CD3 occupation occurs, causes 
interference with the second T  cell activation pathway re- 
quired for optimal T cell responses. The inhibitory effect of 
LFA3TIP on PHA-P-induced T cell proliferation is suppor- 
tive of this mechanism. Stimulation of PBLs by lectins such 
as PHA-P or Con A has been attributed to the involvement 
of the TCK/CD3  pathway and  accessory cell-dependent 
pathways such as CD2 or CD45. It has been suggested that 
PHA-P directly binds  to CD2 (31-33).  In the presence of 
PHA-P, purified multimeric LFA-3 can replace accessory cell 
functions in the augmentation of T cell activation without 
a second ligand to CD2 (33, 34). LFA3TIP on the other hand 
inhibits,  rather than  costimulates  PHA-P-induced T  cell 
proliferation.  Since LFA3TIP  interacts  with the same epi- 
topes as PI-LFA-3, inhibition of PHA-P-induced T cell acti- 
vation is most likely not due to competition between PHA-P 
and LFA3TIP  for binding sites on CD2. 
In all T cell activation assays described here, purified full- 
length PI-LFA-3 had a different effect on T  cell responses 
than LFA3TIP. It had no effect on MLK or OKT3-induced 
T cell proliferation,  and it augmented rather than inhibited 
PHA-P or mAb Tl12  stimulated  T  cell proliferation.  Be- 
cause of these dramatic differences  between LFA3TIP and var- 
ious other forms of LFA-3 proteins,  it was of importance 
to determine  whether LFA3TIP's inhibitory activity stemmed 
from the fact that it contained only one domain. In addition, 
Damle et al. (35) have  recently reported that an immobilized 
two domain LFA-3/IgG1  fusion protein augmented anti- 
TCK-1 or OKT3-induced CD4 + T cell activation. We have 
not examined the effect of LFA3TIP on the costimulation 
with these mAbs, but have found that LFA3TIP, when im- 
mobilized on plastic in combination with activating anti-CD2 
mAbs, does not augment PBL proliferation (data not shown). 
Again,  the difference in response obtained with these two 
LFA-3/IgG1  fusion proteins  could be due to the fact that 
LFA3TIP contains only one domain of LFA-3, or it could 
be a function of the specific costimulatory mAbs used. We 
therefore constructed a two domain LFA-3/IgG1 fusion pro- 
tein (LFA3FLIgG1) and found that this protein had identical 
MLK inhibitory properties and binding profile as LFA3TIP. 
The CD2 binding epitopes of all forms of purified LFA-3 
(PI-LFA-3, LFA3FLIgG1, and LFA3TIP) were found to be 
identical in mAb competition assays, as well as in binding 
analysis to CD2 site-specific  mutants. CD2 binding epitopes 
determined for LFA3TIP are the same as those published by 
Peterson and Seed (18) for LFA-3 expressed on the surface 
of human RBCs.  We therefore cannot attribute the differ- 
ence in activities of these proteins  to different interactions 
with CD2. 
So far, we cannot exclude the possibility that engagement 
of FcKs on accessory antigen-presenting  or T cells with the 
IgG1 portion of LFA3TIP is a contributing factor to the ac- 
tivity of LFA3TIP. We have used control fusion proteins to 
show that engagement of FcR by itself is not responsible 
for T cell inhibition by LFA3TIP. Human IgG1 fusion pro- 
teins that do not bind to CD2 as well as purified human IgG 
have no effect on any T cell responses examined here and do 
not diminish LFA3TIP's inhibitory effect when added simul- 
taneously to T cell activation assays. However, we cannot yet 
exclude  the possibility that LFA3TIP, through its simultaneous 
interactions with CD2 on T cells and with FcRs on APCs 
(through its IgG1 portion), aligns both cells into a configu- 
ration that is either unfavorable for the transduction of the 
second positive T cell activation signal or is favorable for a 
negative signal either directly to T cells or through the in- 
duction of regulatory cytokines. The lack of inhibition by 
LFA3TIP of anti-CD2 antibody-induced  T cell proliferation 
argues against a mechanism that relies solely on cross-bridging 
of T cells with their cognate partners or on an immobiliza- 
tion of CD2 polarization  that occurs upon cellular interac- 
tions  (7). Rather,  our  data  described  here  suggest  that 
LFA3TIP interferes with an event that functionally  links the 
TCR/CD3 and the CD2 T cell activation pathways. Induc- 
tion of a negative signal to T cells by anti-CD2 mAbs had 
been suggested before by Ohno et al. (11), as well as by Palacios 
and Martinez-Maza (10). However, experiments described by 
these authors do not unequivocally demonstrate that the in- 
hibition of T cell responses is indeed independent of the in- 
terruption of CD2/LFA-3 binding. 
The mechanism by which LFA3TIP inhibits T cell responses 
is under investigation. A LFA-3/IgG1 fusion protein, which 
lacks the functional FcK binding sequences  has been produced 
and is currently being used to determine the contribution 
of the FcK engagement in the inhibition by LFA3TIP. The 
LFA3TIP  activity is clearly different from that of purified 
LFA-3 and of mAbs to CD2 or LFA-3. Inhibition by LFA3TIP 
is not merely dependent on blocking cellular adhesion, but 
220  LFA-3/CD2  Interactions Inhibit T Cell Responses occurs through a signal to T  cells which renders them un- 
responsive to activation through the TCR-CD3 complex. 
The unique properties of LFA3TIP are being exploited to 
induce antigen-specific anergy in organ transplants and au- 
toimmune diseases. 
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